Mirati’s First KRAS Data Look At Least As Good As Amgen’s
Executive Summary
The small biotech firm has traded higher in recent months based on Amgen’s AMG 510 results to date, and saw its share price soar based on initial efficacy data for MRTX849 in lung and colorectal cancers.
You may also be interested in...
Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Finance Watch: Expect A Busy First Half For 2020 IPOs
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.